In this respect we inform you as under: 1 By way of a disclosure dated 8 November 2021 (already available on the website of the stock exchanges) the Company has already disclosed to the stock exchanges that its Board of Directors constituted a Committee of Independent Directors for comprehensive evaluation of various alternatives / options including demerger for restructuring of Companys wholly owned subsidiary Eugia Pharma Specialties Limited focused on sterile / injectables oncology and hormonal products and recommend to the Board of Directors of the Company in the ensuing meeting for further discussion and decision. 2 Currently there is no information which requires disclosure under the Listing Regulations.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
